Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA4 | P22748 | 2/20 | 0.40 |
| ▸ | CA5A | P35218 | 2/20 | 0.40 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.40 |
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Peroxymonophosphate SCHEMBL27826978 | 0.96 | LMNA (0.39) | LMNACA1CA4CA5ACA5B | |
| Peroxymonophosphate SCHEMBL2123988 | 0.96 | LMNA (0.39) | LMNACA1CA4CA5ACA5B | |
| Peroxymonophosphate SCHEMBL1822215 | 0.96 | LMNA (0.39) | LMNACA1CA4CA5ACA5B | |
| Peroxymonophosphate SCHEMBL9747042 | 0.96 | LMNA (0.39) | LMNACA1CA4CA5ACA5B | |
| Peroxymonophosphate SCHEMBL4534353 | 0.96 | — | — | |
| Peroxymonophosphate SCHEMBL7139931 | 0.93 | LMNA (0.37) | LMNACA1CA4CA5ACA5B | |
| Peroxymonophosphate SCHEMBL25249573 | 0.92 | LMNA (0.41) | LMNACA1CA4CA5ACA5B | |
| Peroxymonophosphate SCHEMBL9451046 | 0.92 | LMNA (0.41) | LMNACA1CA4CA5ACA5B | |
| Peroxymonophosphate SCHEMBL9451052 | 0.92 | LMNA (0.41) | LMNACA1CA4CA5ACA5B | |
| Peroxymonophosphate SCHEMBL5790488 | 0.92 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3797 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260108592-A1 | IMMUNOGENIC COMPOSITIONS AND USES THEREOF | PFIZER (US) | 2026-04-23 | — | — | US | claimed |
| US-12569555-B2 | Organically modified mineral micro-particles, methods of preparing the same and uses thereof | CRODA INTERNATIONAL PLC (GB) | 2026-03-10 | — | — | US | claimed |
| US-12569556-B2 | Aluminum based adjuvants for tolerogenic vaccination | EAST CAROLINA UNIVERSITY (US) | 2026-03-10 | — | — | US | claimed |
| EP-4698188-A2 | POLYSACCHARIDE ADJUVANTS FOR USE IN PROTEIN-BASED OR RNA-BASED VACCINES | The Children's Medical Center Corporation (US) | 2026-02-25 | — | — | EP | claimed |
| US-20260049057-A1 | OPIOID HAPTENS, CONJUGATES, VACCINES, AND METHODS OF GENERATING ANTIBODIES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2026-02-19 | — | — | US | claimed |
| US-20260048113-A1 | ADJUVANTED IMMUNOGENIC COMPOSITION AGAINST NEISSERIA MENINGITIDIS B | SANOFI PASTEUR INC. (US) | 2026-02-19 | — | — | US | claimed |
| EP-4687967-A1 | MENINGOCOCCAL PROTEIN BASED VACCINE FORMULATIONS AND METHODS FORMANUFACTURING THEREOF | Serum Institute Of India Private Limited (IN) | 2026-02-11 | — | — | EP | claimed |
| EP-4684013-A1 | NON-HUMAN ANIMALS COMPRISING A GENETICALLY MODIFIED ENDOGENOUS IGHA LOCUS AND METHODS OF MAKING THE SAME | Peking University First Hospital (CN) | 2026-01-28 | — | — | EP | claimed |
| EP-4654991-A2 | HUMAN PAPILLOMAVIRUS, VARICELLA-ZOSTER VIRUS, AND RABIES VIRUS ANTIGENS AND USES THEREOF IN CANCER IMMUNOTHERAPY | The United States of America, as represented by The Secretary, Department of Health and Human Services (US) | 2025-12-03 | — | — | EP | claimed |
| US-20250339510-A1 | POLYNUCLEOTIDE VACCINE FORMULATIONS AND METHODS OF USING THE SAME | IMUNON INC (US) | 2025-11-06 | — | — | US | claimed |
| EP-1017283-B1 | POLYNUCLEOTIDE VACCINE FORMULATIONS | MERCK & CO INC (US) | 2004-12-15 | — | — | EP | claimed |
| US-20040170648-A1 | Vaccine composition comprising at least two valences, one enhanced with adjuvant and not the other | AVENTIS PASTEUR SA (FR) | 2004-09-02 | — | — | US | claimed |
| EP-1429800-A2 | VACCINE AND METHOD FOR TREATMENT OF MOTOR NEURONE DISEASES | YEDA RESEARCH AND DEVELOPMENT Co. LTD. (IL) | 2004-06-23 | — | — | EP | claimed |
| EP-1409013-A1 | VACCINES COMPRISING ALUMINIUM ADJUVANTS AND HISTIDINE | Chiron SRL. (IT) | 2004-04-21 | — | — | EP | claimed |
| WO-2003082327-A2 | COMBINED DNA/PROTEIN VACCINE COMPOSITIONS | BRENNTAG BIOSECTOR A/S (DK) | 2003-10-09 | — | — | WO | claimed |
| WO-2003047500-A2 | VACCINE AND METHOD FOR TREATMENT OF MOTOR NEURONE DISEASES | YEDA RESEARCH AND DEVELOPMENT CO. LTD (IL) | 2003-06-12 | — | — | WO | claimed |
| WO-2003009869-A1 | VACCINES COMPRISING ALUMINIUM ADJUVANTS AND HISTIDINE | CHIRON SRL. (IT) | 2003-02-06 | — | — | WO | claimed |
| US-4334999-A | FROM WATER INSOLUBLE COMPOUND DISPERSED IN AQUEOUS SOLUTION BY ION EXCHANGE WITH ALKYL ACID PHOSPHATE AND SOLVENT EXTRACTION | BOARD OF TRUSTEES, MICHIGAN STATE UNIVERSITY (US) | 1982-06-15 | — | — | US | claimed |
| EP-0030067-A1 | Process for the extraction of metal ions | THE BOARD OF TRUSTEES OF THE MICHIGAN STATE UNIVERSITY (US) | 1981-06-10 | — | — | EP | claimed |
| US-4110492-A | METHOD FOR ENCAPSULATING WATER-INSOLUBLE PARTICLES | THE HARSHAW CHEMICAL COMPANY (US) | 1978-08-29 | — | — | US | claimed |